Literature DB >> 27918310

Pancreatic Cancer Surgery: The New R-status Counts.

Oliver Strobel1, Thomas Hank, Ulf Hinz, Frank Bergmann, Lutz Schneider, Christoph Springfeld, Dirk Jäger, Peter Schirmacher, Thilo Hackert, Markus W Büchler.   

Abstract

OBJECTIVE: To assess the relevance of resection margin status for survival outcome after resection and adjuvant therapy for pancreatic cancer.
BACKGROUND: The definitions for R0 and R1 margin status after resection for pancreatic cancer are controversial. The strict definition of R0 requiring a 1 mm tumor-free margin is not commonly accepted. Reported R0/R1 rates and associated survival are highly heterogeneous.
METHODS: A standardized protocol with rigorous assessment of circumferential margins and the R0 definition with a 1 mm free margin were introduced into clinical routine in 2005. From a prospective database, patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma between January 1, 2006 and December 12, 2012 were identified. The rates of R0 (≥1 mm margin), R1 (<1 mm clearance), and R1 (direct margin involvement) status and associated survival were assessed by uni- and multivariable analyses.
RESULTS: Of 561 patients included, 112 patients (20.0%) had R0 and 449 patients (80.0%) had R1 resections, including 123 (21.9%) R1 (≤1 mm) and 326 (58.1%) R1 (direct) resections. A total of 438 (85.9%) received adjuvant therapy. With R0, R1 (<1 mm), and R1 (direct) status the median survival times and 5-year survival rates were 41.6, 27.5, and 23.4 months; and 37.7%, 30.1%, and 20.3%, respectively (P < 0.0001). By multivariable analysis, margin status was confirmed to be independently associated with survival.
CONCLUSIONS: In the context of adjuvant therapy, the resection margin status remains an important independent determinant of postresection survival. R0/R1 resection rates and associated survival vary significantly with the definitions used. An international consensus is urgently needed to achieve comparability with respect to studies and protocols on patients with adjuvant therapy.

Entities:  

Mesh:

Year:  2017        PMID: 27918310     DOI: 10.1097/SLA.0000000000001731

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  62 in total

1.  Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study.

Authors:  Christof Kaltenmeier; Ibrahim Nassour; Richard S Hoehn; Sidrah Khan; Alison Althans; David A Geller; Alessandro Paniccia; Amer Zureikat; Samer Tohme
Journal:  J Gastrointest Surg       Date:  2020-12-02       Impact factor: 3.452

2.  Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer.

Authors:  Masayuki Tanaka; Yosuke Inoue; Kiyoshi Matsueda; Makiko Hiratsuka; Mariko Muto; Shoji Kawakatsu; Yoshihiro Ono; Yoshihiro Mise; Takeaki Ishizawa; Hiromichi Ito; Yu Takahashi; Yutaka Takazawa; Akio Saiura
Journal:  J Gastrointest Surg       Date:  2019-04-01       Impact factor: 3.452

3.  Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.

Authors:  Asmita Chopra; Mazen Zenati; Melissa E Hogg; Herbert J Zeh; David L Bartlett; Nathan Bahary; Amer H Zureikat; Joal D Beane
Journal:  Ann Surg Oncol       Date:  2021-05-23       Impact factor: 5.344

4.  Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety.

Authors:  Yosuke Inoue; Akio Saiura; Atsushi Oba; Shoji Kawakatsu; Yoshihiro Ono; Takafumi Sato; Yoshihiro Mise; Takeaki Ishizawa; Yu Takahashi; Hiromichi Ito
Journal:  J Gastrointest Surg       Date:  2018-10-10       Impact factor: 3.452

5.  A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status.

Authors:  Emanuele F Kauffmann; Niccolò Napoli; Francesca Menonna; Sara Iacopi; Carlo Lombardo; Juri Bernardini; Gabriella Amorese; Andrea Cacciato Insilla; Niccola Funel; Daniela Campani; Carla Cappelli; Davide Caramella; Ugo Boggi
Journal:  Surg Endosc       Date:  2018-06-25       Impact factor: 4.584

6.  Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection?

Authors:  Stefan Heinrich
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

7.  Tumour origin and R1 rates in pancreatic resections: towards consilience in pathology reporting.

Authors:  Munita Bal; Swapnil Rane; Sanjay Talole; Mukta Ramadwar; Kedar Deodhar; Prachi Patil; Mahesh Goel; Shailesh Shrikhande
Journal:  Virchows Arch       Date:  2018-08-08       Impact factor: 4.064

8.  Pathological analysis of the superior mesenteric artery boundary in preoperative computed tomography of resectable pancreatic head adenocarcinoma.

Authors:  Meng Lu; Chun-Hui Yuan; Ling-Fu Zhang; Lian-Yuan Tao; Ying Peng; Li-Mei Guo; Gang Li; Dian-Rong Xiu
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

9.  Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Roberto J Rivero-Soto; Jun Yu; Ammar A Javed; Richard A Burkhart; Inne H M Borel Rinkes; I Quintus Molenaar; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-03-23       Impact factor: 12.969

10.  Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore.

Authors:  Thinzar M Lwin; Takashi Murakami; Kentaro Miyake; Paul J Yazaki; John E Shivley; Robert M Hoffman; Michael Bouvet
Journal:  Ann Surg Oncol       Date:  2018-01-25       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.